Researchers identified hidden gene deletions that explain severe Friedreich ataxia cases previously misdiagnosed by standard testing, distinguishing covert FXN copy loss from repeat expansion patterns. The finding clarifies a pathway to improved genetic accuracy for patients with unusually severe phenotypes. For clinical genomics, the study highlights the risk of relying on a single test modality when repeat expansions and structural variants can generate overlapping diagnostic signals. It also suggests that certain patients may benefit from deletion-aware workflows or orthogonal confirmation. The immediate impact is more accurate classification for prognosis and trial eligibility, since treatment development increasingly depends on precise molecular diagnosis.